智通财经APP获悉,今日(11月29日),中国国家药监局药品审评中心(CDE)官网最新公示,阿斯利康(AZN.US)申报的1类新药AZD5462片获得临床试验默示许可,拟开发治疗心力衰竭。根据阿斯利康官网资料,这是一款RXFP1激动剂小分子药物,目前在国际范围内处于2期临床研究阶段。通过CDE官网查询可知,这是该药首次在中国获批临床。截图来源:CDE官网据悉,RXFP1是一种松弛素受体,该受体在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.